Zinman et al. — EMPA-REG OUTCOME¶

One-paragraph summary¶

People with T2D and established cardiovascular disease received empagliflozin or placebo on background care. MACE HR was 0.86; cardiovascular death fell 38%, heart-failure hospitalisation 35% and all-cause death 32% (PMID 26378978; registration NCT01131676 verified live).

Key findings¶

Benefits emerged too quickly to be explained by HbA1c alone.
Heart-failure and mortality effects reframed diabetes drug development.

Limitations¶

Established-CVD population limits low-risk absolute-effect extrapolation.
Trial did not isolate a single mechanism.

Why it matters¶

It began the organ-protection era and redirected guidelines toward outcome phenotype rather than glucose alone.

Cited by wiki pages¶

Clinical trials landscape
Complications
Glycaemic management and legacy trials
Guidelines
Incretin therapies
Overview
Patient experience and advocacy
Red flags and safety
SGLT2 inhibitors
Youth-onset T2D